Dec 13 2021

Halberd Successfully Eradicates Interluekin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

By |2021-12-12T18:23:45-05:00December 13th, 2021|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, December 13, 2021 – Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Interleukin-1 is associated with numerous diseases ranging from autoimmune to Multiple Sclerosis and Alzheimer’s Disease.   Halberd’s demonstrated ability to control the levels of IL-1, coupled with its previous ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By |2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine ...

Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By |2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Go to Top